Content about Inspire

April 30, 2013
Revamped Adidas personal care collection for men, women hits market

A revamped Adidas personal care range has hit the market, reflecting the athletic energy of today’s man and the confidence of the modern woman.

NEW YORK — A revamped Adidas personal care range has hit the market, reflecting the athletic energy of today’s man and the confidence of the modern woman.

The new collection for men includes body sprays, deodorants, antiperspirants, and hair and body washes. With bold graphics and striking colors, the entire packaging redesign was executed with the dynamic modern Adidas man in mind.

May 16, 2011
Merck closes Inspire acquisition

Drug maker Merck has completed its acquisition of eye care company Inspire.

WHITEHOUSE STATION, N.J. — Drug maker Merck has completed its acquisition of eye care company Inspire.

As previously reported, Merck announced its plan to acquire the company for $5 per share in cash, or $430 million. In addition, Monarch Transaction, a wholly-owned subsidiary of Merck, has merged with and into Inspire, with Inspire surviving as a wholly owned subsidiary of Merck, effective today.

April 28, 2011
Merck closer to acquiring Inspire

Merck has cleared a hurdle in its effort to buy eye care company Inspire Pharmaceuticals for $430 million, the company said Thursday.

WHITEHOUSE STATION, N.J. — Merck has cleared a hurdle in its effort to buy eye care company Inspire Pharmaceuticals for $430 million, the company said Thursday.

The expiration of the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 brings Merck one step closer to acquiring Inspire.

Merck announced its intention to buy Raleigh, N.C.-based Inspire for $5 per share on April 15.

April 5, 2011
Merck eyes Inspire

Drug maker Merck is looking to boost its eye care portfolio by acquiring a company focused on developing and commercializing ophthalmic products. The deal carries a cash value of about $430 million.

WHITEHOUSE STATION, N.J. — Drug maker Merck is looking to boost its eye care portfolio by acquiring a company focused on developing and commercializing ophthalmic products. The deal carries a cash value of about $430 million.